Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort.

RTX therapy for pediatric rheumatic diseases is well-tolerated and results in variable repletion and normalization of B cell numbers at 6 and 12 months. B cell repletion in children is variable and independent of underlying disease and of the number of RTX infusions.